Analysts expect Regional Management Corp. (NYSE:RM) to report $0.68 EPS on May, 1.They anticipate $0.03 EPS change or 4.62% from last quarter’s $0.65 EPS. RM’s profit would be $7.99M giving it 12.13 P/E if the $0.68 EPS is correct. After having $0.62 EPS previously, Regional Management Corp.’s analysts see 9.68% EPS growth. The stock increased 2.01% or $0.65 during the last trading session, reaching $33. About 37,733 shares traded. Regional Management Corp. (NYSE:RM) has risen 60.49% since April 17, 2017 and is uptrending. It has outperformed by 48.94% the S&P500.
Vanda Pharmaceuticals Inc (VNDA) investors sentiment decreased to 1.17 in 2017 Q4. It’s down -0.26, from 1.43 in 2017Q3. The ratio turned negative, as 62 hedge funds started new or increased equity positions, while 53 sold and reduced equity positions in Vanda Pharmaceuticals Inc. The hedge funds in our database now hold: 39.77 million shares, up from 38.89 million shares in 2017Q3. Also, the number of hedge funds holding Vanda Pharmaceuticals Inc in top ten equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 19 Reduced: 34 Increased: 46 New Position: 16.
Ratings analysis reveals 100% of Vanda Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Vanda Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $24.0. The stock’s average target of $22.50 is 49.50% above today’s ($15.05) share price. VNDA was included in 2 notes of analysts from November 9, 2016. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Outperform” rating given on Wednesday, April 12 by Oppenheimer. On Wednesday, November 9 the stock rating was initiated by Aegis Capital with “Buy”.
Since January 1, 0001, it had 0 buys, and 8 selling transactions for $4.89 million activity.
The stock decreased 0.33% or $0.05 during the last trading session, reaching $15.05. About 269,841 shares traded. Vanda Pharmaceuticals Inc. (VNDA) has risen 15.63% since April 17, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $766.62 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
Armistice Capital Llc holds 4.06% of its portfolio in Vanda Pharmaceuticals Inc. for 2.68 million shares. Palo Alto Investors Llc owns 4.16 million shares or 2.72% of their US portfolio. Moreover, Great Point Partners Llc has 2.07% invested in the company for 797,531 shares. The California-based Venbio Select Advisor Llc has invested 1.39% in the stock. Birchview Capital Lp, a Vermont-based fund reported 88,000 shares.
Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on May, 1. They expect $-0.14 earnings per share, up 17.65% or $0.03 from last year’s $-0.17 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 250.00% negative EPS growth.
Investors sentiment increased to 1.12 in Q4 2017. Its up 0.25, from 0.87 in 2017Q3. It improved, as 2 investors sold Regional Management Corp. shares while 31 reduced holdings. 13 funds opened positions while 24 raised stakes. 10.32 million shares or 2.46% more from 10.07 million shares in 2017Q3 were reported. 1,680 are owned by Parallax Volatility Advisers Limited Partnership. Bancorporation Of Ny Mellon invested in 85,184 shares. Moreover, Interest Grp Incorporated Inc has 0% invested in Regional Management Corp. (NYSE:RM) for 6,872 shares. 1,200 are held by Macquarie Ltd. Argent Mngmt Ltd Limited Liability Company owns 7,820 shares. Vanguard Group Inc has invested 0% in Regional Management Corp. (NYSE:RM). Comml Bank Of Montreal Can holds 0% or 387 shares. Aqr Cap Mngmt Limited Liability Corp, Connecticut-based fund reported 266,642 shares. Invesco has 62,512 shares for 0% of their portfolio. Ny State Common Retirement Fund has invested 0% in Regional Management Corp. (NYSE:RM). D E Shaw And Inc reported 0% in Regional Management Corp. (NYSE:RM). Matarin Mgmt Limited Co reported 0.19% in Regional Management Corp. (NYSE:RM). Numeric Limited Liability Corp owns 283,891 shares. Tieton Mngmt Ltd Liability Com has 5.47% invested in Regional Management Corp. (NYSE:RM) for 242,255 shares. Rhumbline Advisers, a Massachusetts-based fund reported 10,077 shares.
Since December 29, 2017, it had 2 insider purchases, and 2 sales for $523,598 activity. Another trade for 2,400 shares valued at $74,912 was bought by Campos Roel C. Taggart Daniel J. had sold 3,200 shares worth $97,440 on Monday, February 26. Shares for $214,300 were bought by BASSWOOD CAPITAL MANAGEMENT – L.L.C. on Friday, December 29.
Regional Management Corp., a diversified consumer finance company, provides various loan products primarily to clients with limited access to consumer credit from banks, thrifts, credit card companies, and other traditional lenders. The company has market cap of $387.63 million. The firm offers small and large installment loans; automobile purchase loans; loans to finance the purchase of furniture, appliances, and other retail products; optional payment products, including credit life, credit accident and health, credit property insurance, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. It has a 12.99 P/E ratio. The Company’s loan products are secured and structured on a fixed rate, fixed term basis with fully amortizing equal monthly installment payments, and repayable at any time without penalty.